Investigational GLP-1-Based Medicine Uses Triple Targeting to Accelerate Weight Loss

In this episode of Science Snapshot, learn how retatrutide, an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showed 28.3% average weight loss at 80 weeks, surpassing currently approved injectables in separate trials.

Science Snapshot GLP1

A “next-generation” GLP-1-based medicine may be setting a new benchmark for weight loss drugs. In May 2026, new trial results for retatrutide, an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showed that average weight loss reached 28.3% at 80 weeks—surpassing the weight-loss results of currently approved injectables in separate trials.

Watch the full video to learn more about how this medicine works and what it might mean for patient care.

 

Explore a Related Course

GLP-1-Based Therapies: Mechanisms of Action, Development, and Clinical Impact

Understand the science behind GLP-1-based therapies and how they’re revolutionizing patient care. 

  • HMX Online Learning
  • Online; Self-Paced
  • Start Today
  • Group Enrollment Option

Dates: Always Available

For: Clinicians and health care professionals; biomedical and translational researchers; professionals in the pharmaceutical, biotechnology, and digital health sectors.

Clinical Drug Development: Clinical Trial Methodologies and Innovations

Learn how therapeutics are assessed during clinical drug development.

  • HMX Online Learning
  • Online; Instructor-Paced
  • Group Enrollment Option
  • Registration Deadline Approaching:

Dates: -

For: Pharmaceutical professionals or researchers; professionals in related sectors; health care professionals